Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Adline Chem Lab Ltd. Share Price
Day's Range
Day's Range
Low
₹
High
₹
Price Summary
| Previous Close | ₹12.12 |
|---|---|
| Day's Range | ₹12.12 - ₹12.50 |
| Open | ₹12.50 |
| 52 Week Range | ₹07.60 - ₹17.06 |
| Volume | 800 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 0.10 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -0.48 |
| P/E Ratio | 0.00 |
| Book Value(₹) | -4.49 |
| PAT Margin (%) | 0.00 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 0.00 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 0.0 | 0.0 |
| Expenses | N/A | N/A |
| PBT | -0.59 | -2.06 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -0.51 | -1.32 |
About Adline Chem Lab Ltd.
| Founded | 1988 |
|---|---|
| Managing Director | Sarang Pathak |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,63,179.62 | 1,933.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,43,301.95 | 9,232.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,88,622.52 | 5,004.40 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,25,998.49 | 8,715.00 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,16,114.43 | 1,151.20 | 835.50 - 835.50 |
| Lenskart Solutions Ltd. | 1,15,446.45 | 668.55 | 0.00 - 0.00 |
| Cipla Ltd. | 1,14,554.33 | 1,413.15 | 1,165.70 - 1,165.70 |
| Laurus Labs Ltd. | 1,00,498.07 | 1,863.00 | 823.10 - 823.10 |
| Lupin Ltd. | 98,312.16 | 2,152.60 | 1,875.00 - 1,875.00 |
| Manipal Health Enterprises Ltd. | 98,258.68 | 709.15 | 625.45 - 625.45 |
No Records Found
Latest News
GlaxoSmithKline Pharmaceuticals informs about press release
Samrat Pharmachem informs about newspaper publication
Hikal informs about investors meet
Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hikal has informed that Analysts and Institutional Investors (‘Participants’) are scheduled to visit the Company's Pune R&T centre and interact with the Company's officials, as per the details enclosed. Discussions will be based on publicly available information.
The above information is a part of company’s filings submitted to BSE.
Parmax Pharma informs about disclosure
SMS Pharmaceuticals informs about credit rating
Pursuant to 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SMS Pharmaceuticals has informed that the CARE Ratings vide their letter No. CARE/HRO/RL/2026-27/1219 dated 01st September, 2026 has reaffirmed/revised its ratings assigned to the bank facilities of the Company. The company has enclosed the summary of ratings for the Company. The rating letter received from CARE Ratings (CARE) is attached as Annexure.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Adline Chem Lab Ltd. is ₹12.12 as of 2026-09-02.
The market capitalisation of Adline Chem Lab Ltd. is ₹7.46 as of 2026-09-01.
The 1-year return of Adline Chem Lab Ltd. is % as of .
The P/E ratio of Adline Chem Lab Ltd. is 0.00 as of 2026-09-02.
The 52-week high and low of Adline Chem Lab Ltd. are ₹17.06 and ₹7.60, respectively, as of 2026-09-02.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
